EichorEICHOR
Location: Ypsilanti Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Ypsilanti

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · National Cancer Institute (NCI) · NCT05564390Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · NRG Oncology · NCT05624996Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · National Cancer Institute (NCI) · NCT07437950Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · Alliance for Clinical Trials in Oncology · NCT07321652Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Huron Gastroenterology PC · Alliance for Clinical Trials in Oncology · NCT07091617Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · SWOG Cancer Research Network · NCT06769126LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Phase 3 · Tenax Investigational Site · Tenax Therapeutics, Inc. · NCT07288398Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Huron Gastroenterology PC · NRG Oncology · NCT05174169Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing
NA · St. Joseph Mercy Health System · University of British Columbia · NCT04634240Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · Alliance for Clinical Trials in Oncology · NCT06931340A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Phase 4 · Huron Gastroenterology Associates, P.C. · Takeda · NCT06095128A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Trinity Health St. Joseph Mercy Ann Arbor /ID# 232190 · AbbVie · NCT04928846ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · Alliance for Clinical Trials in Oncology · NCT06876714A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Phase 3 · Huron Gastroenterology Associates - Center for Digestive Car · Ipsen · NCT06016842A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre
Phase 3 · Investigative Site US012 · Incyte Corporation · NCT07522073Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Huron Gastroenterology PC · National Cancer Institute (NCI) · NCT04269902Prevail Global Study
NA · Saint Joseph Mercy Ann Arbor · Medtronic Vascular · NCT06535854Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA
Phase N/A · Trinity Health Ann Arbor Hospital · CathVision ApS · NCT07275151An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA
NA · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · Wake Forest University Health Sciences · NCT06904391Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · Alliance for Clinical Trials in Oncology · NCT06632977Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Huron Gastroenterology PC · Alliance for Clinical Trials in Oncology · NCT04242095CCM OPEN HF Registry
Phase N/A · Trinity Ann Arbor d/b/a Michigan Heart Ann Arbor · Impulse Dynamics · NCT07112924Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli
Phase 3 · St. Joseph Mercy Hospital - Huron Gastroenterology Associate · Merck Sharp & Dohme LLC · NCT06651281Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · National Cancer Institute (NCI) · NCT05256225A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Phase 3 · 89bio Clinical Study Site · 89bio, Inc. · NCT06419374Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · Trinity Health · SynDevRx, Inc. · NCT05455619Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · National Cancer Institute (NCI) · NCT05554393Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · National Cancer Institute (NCI) · NCT06498635Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology Ann Arb · NRG Oncology · NCT05327686
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.